Corporation
Organon Canada Inc.
- Meetings this Parliament
- 15
- With MPs
- 5
- Since Nov 2021
- 26
- Active registrations
- 1
Most recent reported meeting: Sep 2, 2026.
Lobbying by Organon Canada Inc.: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.
← LobbyingRegistrations in effect
In-house (corporation) In effect since Jun 1, 2026
Filed by Dominic Bégin, President & Managing Director
Lobbyists
- Anne Mayrand · Head, Legal Affairs and Compliance
- Dominic Bégin · President & Managing Director
- Geneviève Gauthier · Executive Director, Corporate Affairs
- Hugues Poulin · Associate Director, Policy & Access
- Jacqueline McCarles · Associate Director, Policy & Access
- Valérie Joseph · Regulatory Affairs & Pharmacovigilance
Institutions they may lobby: Correctional Service of Canada (CSC), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Indigenous Services Canada (ISC), Innovation, Science and Economic Development Canada (ISED), National Defence (DND), Senate of Canada
What they're lobbying on (6)Hide details
- To advocate for the adoption of Bill S-243 ("An Act to establish a national framework for women's health in Canada").
- To recommend policies that will attract increased investment in the pharmaceutical and well being industry, such as on policies, research programs and policies and the Innovation Agenda.
- To actively promote the value of the pharmaceutical industry for Canada's economic health and well being, but more importantly for the health and well being of its citizens and to propose solutions for integrated health care in Canada.
- To actively promote the enhancement of publicly funded women’s health initiatives and programs, including the development of a Pan Canadian Women’s Health Strategy.
- Representations relating to the conditions under which biosimilar drugs are marketed and reimbursed in Canada. More specifically, representations are made to support a favorable and knowledgeable environment to implement new or improve current women’s health programs, the integration of biosimilar drugs into the drug plans administered by the Federal Government and to emphasize the importance that the federal government respect their respective jurisdiction with respect to the approval, marketing and reimbursement of Organon's products.
- Organon Canada’s objective is to preserve a regulatory framework which creates a favourable business environment for the development of the life science sector, including biosimilar drugs and women’s health products, which are the company’s main sectors of activities.
Registration 965297-369785-14. Look it up in the official Registry
Reported meetings
SpreadsheetFiled by Michael Casia (25), Dominic Bégin (1).
-
Reported by Dominic Bégin · In-house (corporation)
- Marjorie Michel · Minister of Health, Health Canada (HC)
To actively promote the enhancement of publicly funded women’s health initiatives and programs, including the development of a Pan Canadian Women’s Health Strategy. Read more
-
Reported by Michael Casia · In-house (corporation)
- Danièle Henkel · Senator, Senate of Canada
To advocate for the adoption of Bill S-243 ("An Act to establish a national framework for women's health in Canada").
-
Reported by Michael Casia · In-house (corporation)
- Danièle Henkel · Senator, Senate of Canada
To advocate for the adoption of Bill S-243 ("An Act to establish a national framework for women's health in Canada").
-
Reported by Michael Casia · In-house (corporation)
- Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
Representations relating to the conditions under which biosimilar drugs are marketed and reimbursed in Canada. More specifically, representations are made to support a favorable and knowledgeable environment to implement new or improve current women’s health programs, the integration of biosimilar drugs into the drug plans administered by the Federal Government and to emphasize the importance that the federal government respect their respective jurisdiction with respect to the approval, marketing and reimbursement of Organon's products. Read more
-
Reported by Michael Casia · In-house (corporation)
- Danièle Henkel · Senator, Senate of Canada
To actively promote the enhancement of publicly funded women’s health initiatives and programs, including the development of a Pan Canadian Women’s Health Strategy. Read more
Organon Canada’s objective is to preserve a regulatory framework which creates a favourable business environment for the development of the life science sector, including biosimilar drugs and women’s health products, which are the company’s main sectors of activities.
-
Reported by Michael Casia · In-house (corporation)
- Shahad Khalladi · Senior Policy Advisor to the Minister of Health, Health Canada (HC)
To actively promote the enhancement of publicly funded women’s health initiatives and programs, including the development of a Pan Canadian Women’s Health Strategy. Read more
Organon Canada’s objective is to preserve a regulatory framework which creates a favourable business environment for the development of the life science sector, including biosimilar drugs and women’s health products, which are the company’s main sectors of activities.
-
Reported by Michael Casia · In-house (corporation)
- Ian Cameron · Director of Strategy and Senior Advisor to the Minister of Industry, Innovation, Science and Economic Development Canada (ISED)
- Manuela Tomic · Senior Policy Advisor to the Minister of Industry, Innovation, Science and Economic Development Canada (ISED)
To actively promote the enhancement of publicly funded women’s health initiatives and programs, including the development of a Pan Canadian Women’s Health Strategy. Read more
Organon Canada’s objective is to preserve a regulatory framework which creates a favourable business environment for the development of the life science sector, including biosimilar drugs and women’s health products, which are the company’s main sectors of activities.
-
Reported by Michael Casia · In-house (corporation)
- Mary Robinson · Senator, Senate of Canada
To actively promote the enhancement of publicly funded women’s health initiatives and programs, including the development of a Pan Canadian Women’s Health Strategy. Read more
Organon Canada’s objective is to preserve a regulatory framework which creates a favourable business environment for the development of the life science sector, including biosimilar drugs and women’s health products, which are the company’s main sectors of activities.
-
Reported by Michael Casia · In-house (corporation)
- Krista Ross · Senator, Senate of Canada
Organon Canada’s objective is to preserve a regulatory framework which creates a favourable business environment for the development of the life science sector, including biosimilar drugs and women’s health products, which are the company’s main sectors of activities. Read more
To actively promote the enhancement of publicly funded women’s health initiatives and programs, including the development of a Pan Canadian Women’s Health Strategy.
-
Reported by Michael Casia · In-house (corporation)
- Louis Plamondon · Member of Parliament
To actively promote the enhancement of publicly funded women’s health initiatives and programs, including the development of a Pan Canadian Women’s Health Strategy. Read more
Organon Canada’s objective is to preserve a regulatory framework which creates a favourable business environment for the development of the life science sector, including biosimilar drugs and women’s health products, which are the company’s main sectors of activities.
-
Reported by Michael Casia · In-house (corporation)
- Marilyn Gladu · Member of Parliament
Organon Canada’s objective is to preserve a regulatory framework which creates a favourable business environment for the development of the life science sector, including biosimilar drugs and women’s health products, which are the company’s main sectors of activities. Read more
To actively promote the enhancement of publicly funded women’s health initiatives and programs, including the development of a Pan Canadian Women’s Health Strategy.
-
Reported by Michael Casia · In-house (corporation)
- Tom Kmiec · Member of Parliament
Organon Canada’s objective is to preserve a regulatory framework which creates a favourable business environment for the development of the life science sector, including biosimilar drugs and women’s health products, which are the company’s main sectors of activities. Read more
To actively promote the enhancement of publicly funded women’s health initiatives and programs, including the development of a Pan Canadian Women’s Health Strategy.
-
Reported by Michael Casia · In-house (corporation)
- Mohamed-Iqbal Ravalia · Senator, Senate of Canada
To actively promote the enhancement of publicly funded women’s health initiatives and programs, including the development of a Pan Canadian Women’s Health Strategy. Read more
Organon Canada’s objective is to preserve a regulatory framework which creates a favourable business environment for the development of the life science sector, including biosimilar drugs and women’s health products, which are the company’s main sectors of activities.
-
Reported by Michael Casia · In-house (corporation)
- Mélanie Joly · Minister of Industry and Minister responsible for Canada Economic Development for Quebec Regions, Innovation, Science and Economic Development Canada (ISED)
Organon Canada’s objective is to preserve a regulatory framework which creates a favourable business environment for the development of the life science sector, including biosimilar drugs and women’s health products, which are the company’s main sectors of activities. Read more
-
Reported by Michael Casia · In-house (corporation)
- Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
Organon Canada’s objective is to preserve a regulatory framework which creates a favourable business environment for the development of the life science sector, including biosimilar drugs and women’s health products, which are the company’s main sectors of activities. Read more
-
Reported by Michael Casia · In-house (corporation)
- Andréanne Larouche · Member of Parliament
- Marilou McPhedran · Senator, Senate of Canada
- Mary Jane McCallum · Senator, Senate of Canada
- Mohamed-Iqbal Ravalia · Senator, Senate of Canada
and 1 moreShow fewer
- Flordeliz Osler · Senator, Senate of Canada
To actively promote the enhancement of publicly funded women’s health initiatives and programs, including the development of a Pan Canadian Women’s Health Strategy. Read more
Organon Canada’s objective is to preserve a regulatory framework which creates a favourable business environment for the development of the life science sector, including biosimilar drugs and women’s health products, which are the company’s main sectors of activities.
-
Reported by Michael Casia · In-house (corporation)
- Ya'ara Saks · Minister of Mental Health and Addictions and Associate Minister of Health, Health Canada (HC)
To actively promote the enhancement of publicly funded women’s health initiatives and programs, including the development of a Pan Canadian Women’s Health Strategy. Read more
Representations relating to the conditions under which biosimilar drugs are marketed and reimbursed in Canada. More specifically, representations are made to support a favorable and knowledgeable environment to implement new or improve current women’s health programs, the integration of biosimilar drugs into the drug plans administered by the Federal Government and to emphasize the importance that the federal government respect their respective jurisdiction with respect to the approval, marketing and reimbursement of Organon's products.
Organon Canada’s objective is to preserve a regulatory framework which creates a favourable business environment for the development of the life science sector, including biosimilar drugs and women’s health products, which are the company’s main sectors of activities.
To actively promote the value of the pharmaceutical industry for Canada's economic health and well being, but more importantly for the health and well being of its citizens and to propose solutions for integrated health care in Canada.
-
Reported by Michael Casia · In-house (corporation)
- Mark Holland · Minister of Health, Health Canada (HC)
Organon Canada’s objective is to preserve a regulatory framework which creates a favourable business environment for the development of the life science sector, including biosimilar drugs and women’s health products, which are the company’s main sectors of activities. Read more
To actively promote the enhancement of publicly funded women’s health initiatives and programs, including the development of a Pan Canadian Women’s Health Strategy.
-
Reported by Michael Casia · In-house (corporation)
- Emelyana Titarenko · Senior Advisor, Communications and Issues, Health Canada (HC)
Health
-
Reported by Michael Casia · In-house (corporation)
- Karen Vecchio · Member of Parliament, House of Commons
Health
-
Reported by Michael Casia · In-house (corporation)
- Luc Thériault · Member of Parliament
Health
-
Reported by Michael Casia · In-house (corporation)
- Jenna Sudds · Member of Parliament
Health
-
Reported by Michael Casia · In-house (corporation)
- Luc Berthold · Member of Parliament
- Pierre Paul-Hus · Member of Parlliament
- Laila Goodridge · Member of Parliament
- Pierre-Hughes Boisvenu · Senator, Senate of Canada
Health
-
Reported by Michael Casia · In-house (corporation)
- Joanna Lam · Regional Advisor, Western and Northern Desk, Health Canada (HC)
Health
-
Reported by Michael Casia · In-house (corporation)
- Karen Vecchio · Member of Parliament, House of Commons
Health
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.